Immuno-Oncology Biomarkers: Today’s Imperatives for Tomorrow’s Needs

November 8, 2017 • 8 a.m.-12:30 p.m.


Program Purpose

Current biomarkers to predict response to immunotherapy single agents or to combinations are suboptimal, and at best enrich for clinical responses. Multiple assays have been developed or are in development by industry and academic investigators. Several diagnostic companies or diagnostic divisions of larger pharma have ongoing efforts. Similarly, various assays are in development to characterize the immune microenvironment. Assays are also being developed to determine the pharmacodynamic effects of drugs in tumor or peripheral blood; and blood-based assays to assess response to treatment (changes in tumor burden). While most assays require tissue sampling, efforts are also in progress to develop imaging modalities which can be used for prediction of response (by assessing tumor biological properties and immune infiltrates) pre-treatment or early post-treatment.

The SITC Industry Committee has developed a Biomarkers Fair to allow companies and interested academic investigators to present their latest technology. This forum will provide the opportunity for presentation of multiple biomarker development efforts by all sectors and stimulate interactions between biomarker diagnostic innovators with each other and with end-users.

Presentation Applications

Presentation applications for Immuno-Oncology Biomarkers: Today’s Imperatives for Tomorrow’s Needs were accepted until 5 p.m. PT on Tuesday, Aug. 1. Industry and academic investigators who are working on biomarker development are welcome to submit an application describing their biomarker.

Intended Audience

The intended audience for this program included, but was not limited to basic, translational and clinical researchers; postdoctoral fellows; clinicians; and payers involved in cancer research from such affiliations as academia, industry and regulatory agencies.

Americans with Disabilities Act

handicap.pngEvent staff will be glad to assist you with any special needs (i.e., physical, dietary, etc.). Please contact SITC prior to the live event at +1 414-271-2456.

Program Organizers

This program is organized in collaboration with the SITC Industry Committee. The following individuals are recognized for their leadership in developing this session:

  • Adrian Bot, MD, PhD –  Kite Pharma, Inc.
  • Alessandra Cesano, MD, PhD –  Nanostring, Inc.
  • Daniel S. Chen, MD, PhD –  Genentech
  • David Kaufman, MD, PhD –  Merck Research Laboratories
  • Salil Patel, PhD –  Bristol-Myers Squibb
SITC's Immuno-Oncology Biomarkers: Today's Imperatives for Tomorrow's Needs is supported in part by grants from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Merck & Co., Inc, and Incyte Corporation.